View in EDS HTML Full Text PDF Full Text

382 Lebrikizumab provides clinically meaningful improvements in atopic dermatitis in patients previously treated with dupilumab.

Saved in:
Bibliographic Details
Title: 382 Lebrikizumab provides clinically meaningful improvements in atopic dermatitis in patients previously treated with dupilumab.
Authors: Gold, Linda Stein1 (AUTHOR), Gutermuth, Jan2 (AUTHOR), Adam, David N3,4,5 (AUTHOR), Flohr, Carsten6 (AUTHOR), Weidinger, Stephan7 (AUTHOR), Atwater, Amber Reck8 (AUTHOR), Pierce, Evangeline8 (AUTHOR), Yang, Fan Emily8 (AUTHOR), Chen, Sherry9 (AUTHOR), Pau-Charles, Ignasi10 (AUTHOR), Beck, Lisa A11 (AUTHOR)
Source: British Journal of Dermatology. 2023 Supplement, Vol. 188, p1-3. 3p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:00070963
DOI:10.1093/bjd/ljad162.010